Evidence map›Paper›PMID 20232033›Full record

ReviewDer Nervenarzt2010

[Therapeutic monoclonal antibodies in clinical neurology].

M Buttmann, H Wiendl

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

M ButtmannKlinische Forschungsgruppe MS und Neuroimmunologie, Neurologische Klinik und Poliklinik der Universität Würzburg, Josef-Schneider-Strasse 11, Würzburg, Germany. m.buttmann@uni-wuerzburg.de
H Wiendl
Klinik und Poliklinik für Neurologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant monoclonal antibodies break new ground in the treatment of immune-mediated nerve and muscle disorders but also of neurodegenerative diseases, in the field of neuro-oncology and in pain therapy, as they allow molecular targeting of defined cell populations or key pathophysiological molecules. However, safety risks might accompany a high efficacy. Basic understanding of this increasingly important class of agents and a steady update of knowledge, in particular on safety aspects, are therefore key requirements for responsible use based on an individual benefit-risk assessment.

Indexed as

AlemtuzumabAlzheimer DiseaseAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmCentral Nervous System DiseasesCentral Nervous System NeoplasmsClinical Trials as TopicDrug ApprovalHumansMultiple SclerosisNatalizumabOpportunistic InfectionsRecombinant ProteinsRituximabAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmNatalizumabRecombinant ProteinsRituximab

Identifiers

PMID20232033
OpenAlexW2593691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.